How CGM helps people with
diabetes

CGM = continuous glucose monitoring

NOW APPROVED: The FreeStyle Libre 3 app‡  in iOS for daily insulin users
NOW APPROVED: The FreeStyle Libre 3 app‡  in iOS for daily insulin users
NOW APPROVED: The FreeStyle Libre 3 app‡  in iOS for daily insulin users

See if the FreeStyle Libre 2 system or FreeStyle Libre 3 system is right for you

test

The FreeStyle Libre 2 and FreeStyle Libre 3 systems are FDA-cleared for people 4 years of age and older with Type 1 or Type 2 diabetes1,2. They can be used for:

  • Making treatment decisions anytime*, whether your glucose is high or low, no fingersticks required

  • Tracking changes over time to help spot episodes of hyperglycemia and hypoglycemia1-3

  • Notifying when glucose levels are out of range with optional alarms‡§1,2 (high, low, and signal loss)

test

Do you need help managing your glucose levels?

Ask your doctor about getting started on one of our CGM systems. The FreeStyle Libre CGM systems are available by prescription only.

The FreeStyle Libre family of products are proven to help Type 1 and Type 2 diabetes patients:

  • Lower their A1cII¶4-6

  • Spend less time in high or low glucoseII#7-10

  • Improve their glucose controlII¶4,5,7,8,10-12

Space

Hear from people who have switched to one of the FreeStyle Libre CGM systems

Scott has Type 1 diabetes and was worried about spikes in his A1c

“The thing that's most powerful is the data it gives me.”

Courtney has Type 2 diabetes and found monitoring her glucose with fingersticks difficult

“The data I was able to get now brought light to what was really going on.”

Alyssa has Type 1 diabetes and was embarrassed about testing her blood sugar in public

“The sensor is so inconspicuous that it surprises me when someone asks what it is.”

Michael has Type 2 diabetes and wanted to understand how food affected his glucose levels

“It has taught me not only what to eat, but what not to eat.”

Learn more from people managing their diabetes without fingersticks**

The more affordable CGM systems††13

Most covered patients pay less than $40 per month for FreeStyle Libre CGM sensors‡‡13.
Learn more

Image of pen and calculator

Ready to get started with a FREE§§ trial?

Sign up for the MyFreeStyle program to try one of the FreeStyle Libre CGM systems—at no cost§§.
Let's go

 

Woman with CGM sensor

FreeStyle Libre 2 and FreeStyle Libre 3 systems are indicated for use in people with diabetes ages 4 and older.

Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

* Glucose readings are not available during 1-hour warm-up, when sensor is too hot or too cold, when you see an error or “LO” or “HI” message, or no current glucose reading.

† FreeStyle Libre 2 and FreeStyle Libre 3 systems: Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

‡ Notifications will only be received when alarms are turned on and the sensor is within 20 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 2 User’s Manual for more information.

§ Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User’s Manual for more information.

II Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.

¶ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore, the study data is applicable to both products.

# Data from this study was collected with the FreeStyle Libre 14 day system and FreeStyle LibreLink. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore, the study data is applicable to both products.

** FreeStyle Libre 14 day system: Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

†† Based on a comparison of list prices of the FreeStyle Libre personal CGM systems versus competitors’ CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

‡‡ Based on prescription claims for commercially insured patients using the FreeStyle Libre personal CGM systems. Does not include Medicare, Medicaid, uninsured, and other federal or state healthcare program patients. The actual amount a patient pays may vary. The FreeStyle Libre systems requires a prescription.

§§ or ♢ Eligible patients will receive one (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1, Type 2, or gestational diabetes. Patients ages 18 and older are eligible to sign up and receive an offer for the (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor. Patients ages 4-17 are eligible to receive an offer for the (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Kaiser Permanente, Medicare, Medicaid or other federal or state healthcare programs, residents of Massachusetts, or US territories (other than Puerto Rico). The free (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor is provided as a sample and is limited to one sample per eligible person per product identification number. The FreeStyle Libre 2 sensor or FreeStyle Libre 3 sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.

References: 1. FreeStyle Libre 2 User’s Manual. 2. FreeStyle Libre 3 User’s Manual. 3. Unger, Jeff, Pamela Kushner, and John E. Anderson. "Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care." Postgraduate Medicine 132, no. 4 (2020): 305-313. https://doi.org/10.1080/00325481.2020.1744393. 4. Evans, Mark, et al. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies." Diabetes Therapy 11, no. 1 (2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 5. Kroeger, Jens, Peter Fasching, and Helene Hanaire. "Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes." Diabetes Therapy 11, no. 1 (2020): 279-291. https://doi.org/10.1007/s13300-019-00741-9. 6. Evans, Mark, et al. "Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta analysis of 75 real-world observational studies." Diabetes Therapy (2022). https://doi.org/10.1007/s13300-022-01253-9. 7. Haak, Thomas, et al. "Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55-73.  https://doi.org/10.1007/s13300-016-0223-6. 8. Bolinder, Jan, et al. "Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial." The Lancet 10057, no. 388 (2016): ‍2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5.
9. Kao, Kalvin, et al. "Comparison of glucose metrics between users of CGM readers and CGM-connected apps." Journal of Diabetes Science and Technology (2021). https://doi.org/10.1177/19322968211044141. 10. Dunn, Timothy C., et al. "Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycemic measures: A European analysis of over 60 million glucose tests." Diabetes Research and Clinical Practice 137, no. 37 (2018): 37-46. https://doi.org/10.1016/j.diabres.2017.12.015. 11. Campbell, Fiona M., et al. "Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study." Pediatric Diabetes 19, no. 7 (2018): 1294-1301. https://doi.org/10.1111/pedi.12735. 12. Yaron, Marianna, et al. "Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes." Diabetes Care 42, no. 7 (July 2019); 1178-1184. https://doi.org/10.2337/dc18-0166. 13. Data on File. Abbott Diabetes Care.


ADC-36558 v3.0